Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | LSS | P48449 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3031906 | 0.98 | CYP1A2 (0.54) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL9474398 | 0.96 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL3027364 | 0.94 | CYP1A2 (0.55) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL21409484 | 0.92 | CYP1A2 (0.57) | CYP1A2SIGMAR1EPHX1LSSHTT | |
| SCHEMBL144946 | 0.92 | CYP1A2 (0.61) | CYP1A2SIGMAR1HTTMAPTLMNA | |
| SCHEMBL8744097 | 0.92 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL4923265 | 0.92 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL4921924 | 0.92 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL55638 | 0.92 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 | |
| SCHEMBL1127668 | 0.92 | CYP1A2 (0.48) | CYP1A2SIGMAR1EPHX1LSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212175-B2 | Pharmaceutical hypocholesterolemic compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20120065168-A1 | Pharmaceutical Hypocholesterolemic Compositions | LIPIDEON BIOTECHNOLOGY AG (CH) | 2012-03-15 | — | — | US | disclosed |
| EP-1150673-A4 | MONO-ACYLOXY ARALKYL NEUROMUSCULAR RELAXANTS | NEWLAXANT L L C (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6376510-B1 | ADMINISTERING A ALKOXY- AND ACYLOXY-SUBSTITUTED ARALKYL AND ARALKENYL BIS QUATERNARY AMMONIUM DERIVATIVES OF CYCLIC ALKANOL DIESTERS TO A HUMAN AS MUSCLE RELAXANTS | NEWLAXANT LLC | 2002-04-23 | — | — | US | disclosed |
| EP-1150673-A1 | MONO-ACYLOXY ARALKYL NEUROMUSCULAR RELAXANTS | Newlaxant, L.L.C. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6274623-B1 | DI- OR POLY-ALKOXY-OR ACYLOXY-SUBSTITUTED ARALKYL AND ARAKENYL QUATERNARY AMMONIUM DERIVATIVES OF CYCLIC AMINOALKANOL DIESTERS SUCH AS BIS(N-(3,4-DIPROPIONYLOXY-BENZYL)GRANATANINIUM-3-ALPHA-YL)ADIPATE DIBROMIDE | NEWLAXANT LLC | 2001-08-14 | — | — | US | disclosed |
| US-6274757-B1 | REACTING AN HYDROXY AMINE CORRESPONDING COMPOUND WITH DICHLORO COMPOUND | NEWLAXANT LLC | 2001-08-14 | — | — | US | disclosed |
| EP-1025099-A1 | BIS-QUATERNARY AMMONIUM DERIVATIVES AS NEUROMUSCULAR RELAXANTS | Gyermek, Laszlo (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-2000044377-A1 | MONO-ACYLOXY ARALKYL NEUROMUSCULAR RELAXANTS | NEWLAXANT, L.L.C. (US) | 2000-08-03 | — | — | WO | disclosed |
| US-5990124-A | ALKOXY AND/OR ACYLOXY DI- AND POLY-SUBSTITUTED ARALKYL AND ARALKENYL BIS-QUATERNARY AMMONIUM DERIVATIVES OF CYCLIC ALKANOL DIESTERS; SUCH AS BIS(N-(4-ACETOXY-3-METHOXYBENZYL) TROPANIUM-3-YL)-3,6-ENDOMETHYLENE-1,2,3,6-TETRAHYDROPHTHALATE | GYERMEK LASZLO (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1999021854-A1 | BIS-QUATERNARY AMMONIUM DERIVATIVES AS NEUROMUSCULAR RELAXANTS | NEWLAXANT LLC (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065168-A1 | Pharmaceutical Hypocholesterolemic Compositions | CYP46A1, DHCR7, HMGCR | CYP1A2 736/4885SIGMAR1 3085/4885EPHX1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.